fashion -WSS

fashion

author：explore 2025-09-29 20:51:32 - browse：8289

Cell and gene therapy sign seen at a conference. -- biotech coverage from STAT — Jonathan Wosen for STAT

CARLSBAD, Calif. — Biotech CEOs leading cell and gene therapy companies spoke frankly at a conference here last week about the tough choices they’re making to preserve limited cash amid the industry’s ongoing slowdown.

The company leaders said that they’ve felt added pressure to use smaller teams to work quickly on fewer projects, and at times to partner with outside firms that have specific manufacturing and research expertise. Not all of these changes are bad, they added, noting that efficiency is a good trait for a biotech company in any market.

The candid conversation on Thursday was part of Meeting on the Mesa, an annual cell and gene therapy conference held in Carlsbad, in the north of San Diego County. And it provided a glimpse into discussions happening across the life science industry as biotech markets continue a sharp slump that dates back to late 2021.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： STAT Summit: Michael J. Fox on progress in Parkinson's research

WSS

A new crop of companies is reshaping the health data economy

A new crop of companies is reshaping the health data economy

What to watch for from Zogenix and Amicus clinical trials

How doctors’ personal politics affect patients

Beam Therapeutics to lay off 20% of its staff, re

STAT Summit: How a Chicago ER doctor tackles gun violence

hotspot

fashion

focus

At least 13 dead in Texas as scorching temps continue

The explosion of genetic testing requires a new approach

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Solve the antibiotic resistance crisis with preventive drugs

Hepatitis C has a cure — but many Americans still lack access to it

A new crop of companies is reshaping the health data economy

New air purifier tech could be key to improving indoor air quality

NIH confirmation hearing shows politicization of research

Medicare details structure of new drug price negotiation program

Lawmakers consider Medicare pay reforms for doctors

leisure time

How climate

Roche’s Alnylam deal shows drug firms interested in heart drugs

The EU Joint Clinical Assessment needs to live up to its promise

Studies point to risks of excluding people with obesity from drug trials

STAT Summit: How a Chicago ER doctor tackles gun violence

Device maker Teleflex to acquire urology company for $600M

hotspot

hotspot

hotspot

leisure time